Issue 8, 2018

Methylene violet 3RAX-conjugated porphyrin for photodynamic therapy: synthesis, DNA photocleavage, and cell study

Abstract

A methylene violet 3RAX-conjugated porphyrin has been designed and synthesized as a potential photosensitizer in photodynamic therapy because of its high DNA binding constant and the efficacy in inhibiting cancer cells with subcellular localization.

Graphical abstract: Methylene violet 3RAX-conjugated porphyrin for photodynamic therapy: synthesis, DNA photocleavage, and cell study

Supplementary files

Article information

Article type
Paper
Submitted
09 Dec. 2017
Accepted
16 Janv. 2018
First published
24 Janv. 2018
This article is Open Access
Creative Commons BY license

RSC Adv., 2018,8, 4472-4477

Methylene violet 3RAX-conjugated porphyrin for photodynamic therapy: synthesis, DNA photocleavage, and cell study

S. Yao, Y. Zheng, L. Jiang, C. Xie, F. Wu, C. Huang, X. Zhang, K. Wong, Z. Li and K. Wang, RSC Adv., 2018, 8, 4472 DOI: 10.1039/C7RA13176C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements